My child's age

Tailors each page to their stage — you can change it anytime.

Explained28 min readReviewed September 2026

Autism genetic testing: what it finds, what it costs, and what to ask

Autism genetic testing cannot diagnose autism. Here is what it does find, how often, what it costs, and what to ask before you agree to it.

A sample tube standing beside a report card marked with a small DNA helix

The short answer

  • Autism genetic testing cannot diagnose autism — it looks for an underlying genetic condition in a child who already has the diagnosis, and pooled across autism sequencing studies it finds one in about 17% of children tested (Stefanski 2021).
  • The tests do different jobs: chromosomal microarray reads missing or duplicated chunks of chromosome, fragile X needs its own separate test, and exome or genome sequencing reads the letters inside genes.
  • Yields differ mostly because of who was tested — 9.3% for microarray and 8.4% for exome in one clinic sample (Tammimies 2015), and 31% rising to 53% for exome depending on whether other medical features are present (Srivastava 2019).
  • A result can change screening schedules, unlock condition-specific care and research, and give the family recurrence information. It never sets a ceiling on what your child can do.
  • We do not support or promote prenatal or embryo screening for autism, and deciding not to test at all is a legitimate decision.

If your child is under 5

Ages 0–4
  • This is the age where a result is most likely to change something practical, because a named condition can start a heart, kidney, eye or seizure screening schedule before anything has gone wrong.
  • Yield is higher when there are other medical features alongside autism — feeding, growth, seizures, or heart and kidney findings (Srivastava 2019: 31% for isolated neurodevelopmental conditions, 53% with associated conditions).
  • Action: ask your pediatrician for a genetics referral now rather than after the next milestone review — waits for a genetics appointment are long in most places, and you can still decline the test when you get there.

Changes when you change the age at the top of the page.

If your child is 5 to 8

Ages 5–8
  • School teams sometimes ask whether genetics has been offered. A clear yes, no, or not yet is a complete answer, and a genetic result rarely changes what happens in the classroom.
  • If a condition is named, ask genetics for its screening schedule in writing and give a copy to your pediatrician and the school nurse, so the plan does not live only in your memory.
  • Action: if testing has not happened, ask whether exome or genome sequencing is available to you, and whether your insurer wants a letter of medical necessity first.

Changes when you change the age at the top of the page.

If your child is 9 to 12

Ages 9–12
  • Your child is old enough to want a plain explanation of what is being looked for and what the test cannot answer — and old enough to notice if you avoid the question.
  • This is a good age to ask genetics for a one-page summary written for your child rather than for a clinician.
  • Action: agree with your child, before the appointment, what you will tell them about the result and when — then keep to it, including if the answer is that nothing was found.

Changes when you change the age at the top of the page.

If your child is a teenager

Ages 13–17
  • Your teenager's own view about being tested matters, and carries more weight the closer they get to adulthood.
  • Autistic people have the right to decide about their own genetic information — including the right to decline secondary findings, and the right not to know.
  • Action: bring your teenager into the consent conversation directly, including the choice about secondary findings, rather than deciding it for them in advance.

Changes when you change the age at the top of the page.

How often testing finds an explanationDiagnostic yield, and why the numbers differ
Chromosomal microarray, developmental clinic sample (Tammimies 2015)9.3%
Exome sequencing, same sample, 95 trios (Tammimies 2015)8.4%
Both tests together, those same 95 children (Tammimies 2015)15.8%
Sequencing in autism, pooled across 14 cohorts (Stefanski 2021)17.1%
Exome, isolated neurodevelopmental conditions (Srivastava 2019)31%
Exome, with other associated conditions (Srivastava 2019)53%

Tammimies 2015 (JAMA): 258 children in a developmental clinic — microarray 9.3%, exome 8.4% in the 95 who had trio sequencing, 15.8% for both tests together in those 95. Stefanski 2021 (Epilepsia): 17.1% pooled across autism sequencing studies. Srivastava 2019 (Genetics in Medicine): exome 31% in isolated neurodevelopmental conditions, 53% where other conditions are present. Full citations below.

Can genetic testing diagnose autism, and what can it find?

No. Autism genetic testing is a search for a genetic condition underneath a diagnosis your child already has. That diagnosis was made clinically, from history, observation, and how your child communicates, plays and relates to people. The American Academy of Pediatrics clinical report on identifying, evaluating and managing children with autism spectrum disorder expects primary care clinicians to know the diagnostic criteria and, as a separate matter, appropriate etiologic evaluation — the search for a cause (Hyman 2020). Autism is diagnosed by evaluation, not by a laboratory. If you are still working toward that diagnosis, start with autism testing explained. If a late-night quiz is what brought you here, read are online autism tests accurate? before you take another.

So no sample of blood or saliva puts a child on the spectrum, and none takes a child off it. If a clinic or a company implies otherwise, be careful with everything else they tell you.

What the test can do is find a named genetic condition in a minority of children. Pooled across the autism cohorts in a systematic review of 103 clinical sequencing studies, the diagnostic yield in autism was 17.1% (Stefanski 2021). Read that number in both directions: roughly one child in six gets an explanation, and roughly five in six do not.

Does a genetic finding predict what my child can do?

No. A lab that reports a finding is saying that a change in a particular gene or stretch of chromosome is enough to explain part of your child’s developmental picture. It is not saying that this change is your child.

Nearly everything known about these conditions is population-level information: what has been observed across the people described with that finding so far, often a small group, often studied because they were the most affected. It describes a range, not a prediction about one person.

A named condition may come with a screening schedule, a specialist to see, a research registry to join and a parent community that understands your week. It does not come with a ceiling. If anyone tells you what your child will never do on the basis of a gene name, they have gone beyond what the science supports.

Two more things testing will not do:

  • It will not replace educational evaluation, therapy decisions or support at school.
  • It will not change who your child is. The result was already true before the sample was taken.

And one thing this site will not do: we do not support or promote prenatal or embryo screening for autism. Testing a child who already has a diagnosis, so that their medical care can be better, is a different act from screening a pregnancy or an embryo to decide whether an autistic person should exist. Everything on this page is about the first.

What would a genetic result change for my child?

Mostly medical follow-up, not daily life. Read this section first if you are deciding whether testing is worth the appointment.

Screening schedules. This is the biggest practical gain. Many named genetic conditions come with recommended surveillance — echocardiograms, kidney ultrasounds, eye checks, hearing checks, or watching for seizures — because those problems occur often enough in that condition to look for them before they announce themselves. The 2025 AAP clinical report names surveillance for disorder-related complications among the benefits of establishing a specific diagnosis early (Rodan 2025). Without a name, nobody knows to look.

Condition-specific management. Occasionally a result points to something more specific than surveillance: a medication that suits or does not suit that condition, a dietary consideration, an anesthetic precaution worth putting on the chart before a routine procedure. This is uncommon, and it is real when it happens.

Research and registries. A confirmed genetic finding opens studies that are otherwise closed. SPARK is a large US autism research community for people of any age living in the US with a professional diagnosis of autism, and their family members. Its FAQ says “There is no cost to join SPARK”, that enrollment “usually takes between 15 and 30 minutes”, that the saliva kit for DNA analysis is optional, and that “If we find a genetic change related to autism in your sample, we will contact you.” Simons Searchlight is narrower: it follows families with a confirmed diagnosis of one of the rare genetic neurodevelopmental conditions on its gene list, asks participants to upload their genetic lab report, and covers the cost of any sample collection it asks for. Neither is treatment, and neither is a substitute for care. They let your child’s information count toward what is known about their condition, and often lead to other families with the same one.

Information for your family. Some findings carry a recurrence risk — a known chance of the same thing happening in another pregnancy — and some do not. The 2025 AAP report lists accurate recurrence risk as one of the benefits of establishing a specific diagnosis (Rodan 2025). This is genetic counselor territory, not internet territory, and there is no rush. The information keeps.

School: usually very little. Educational support is driven by what your child needs day to day, not by a gene name. A genetic result rarely changes classroom strategy. It can occasionally help a school understand medical absences, fatigue or a seizure plan, and it can help an argument about whether needs are real. But if the reason you are testing is to get better support at school, testing is an indirect route to a goal that an evaluation and the right diagnostic codes address more directly.

Your child’s own story, later. A named condition is something your child may want, or may not, when they are old enough to ask why autism happens in their own case. Some autistic adults value having the explanation. Others find it beside the point. Both reactions are normal, and neither is yours to decide for them now. That is a good reason to keep the report somewhere they can find it, and to be honest with them about what it does and does not say.

What do medical guidelines say about genetic testing for autism?

Professional bodies have recommended a genetics evaluation after an autism diagnosis for well over a decade. What has changed is which test they recommend first.

ACMG, 2013. The American College of Medical Genetics and Genomics guideline on identifying the etiology of autism spectrum disorders sets out ground rules that still hold. Confirm the autism diagnosis before investigating. Discuss the testing options, the diagnostic yields and the family investment involved before proceeding. Coordinate with the child’s regular medical home, and build an individual plan from that child’s history and features rather than running a fixed list (Schaefer 2013). The instruction to talk about yields with the family up front is the one most often skipped, and you can ask for it by name.

AAP, 2020. The American Academy of Pediatrics clinical report says primary care clinicians should be familiar with appropriate etiologic evaluation alongside diagnosis and the co-occurring conditions that affect a child’s day (Hyman 2020). This is why your pediatrician can raise genetics without waiting for a specialist to think of it.

Srivastava, 2019. A meta-analysis and multidisciplinary consensus statement compared exome sequencing with chromosomal microarray, which had been the standard first test. Exome yield was 36% overall across the included studies, 31% for isolated neurodevelopmental conditions and 53% where other associated conditions were present, against 15–20% in the earlier microarray literature. The group proposed putting exome sequencing at the beginning of the evaluation for unexplained neurodevelopmental conditions rather than at the end.

ACMG, 2021. An evidence-based clinical guideline then made it formal: the ACMG strongly recommends that exome or genome sequencing be considered as a first- or second-tier test for children with congenital anomalies, developmental delay or intellectual disability, noting it has a higher diagnostic yield than standard genetic testing and may be more cost-effective when ordered early (Manickam 2021).

AAP, 2025. The most recent clinical report, on genetic evaluation of the child with intellectual disability or global developmental delay, describes the practical approach for a general pediatrician. Where the clinical picture points to a specific condition, testing should be chosen by phenotype. Where it does not, an agnostic — hypothesis-free — approach is used, with the choice of test based on diagnostic yield and on practical considerations including test complexity and the impact on management (Rodan 2025).

The joint statement, 3 June 2026. The National Society of Genetic Counselors, the American Society of Human Genetics and the American College of Medical Genetics and Genomics issued a short joint statement on genetics and autism. It puts autism at “approximately 1 in 31 children (3.2%)”, says that “hundreds of genes and chromosomal variations are known to increase the likelihood of autism”, and says that better testing and large collaborative studies “have improved the ability to identify likely genetic causes, which can allow early intervention for associated medical conditions to improve outcomes.”

What if nobody has offered us genetics?

That is usually a sign nobody got to it, not that it was considered and ruled out on your behalf. Guidelines describe what should be available, not what every family is offered, and uptake lags them. We have not found a figure for that gap that we can stand behind, so we do not give one.

What you can do is ask. “Has a genetics evaluation been offered to us?” is a fair question at any appointment, and “not yet” is a normal answer that a referral fixes.

What does each genetic test read, and what does it miss?

Each test reads a different part of the genome, and each misses something the others catch. Clinicians rarely say “a genetic test”; they name one, and the names are not self-explanatory.

Chromosomal microarray

A chromosomal microarray scans the chromosomes for stretches of DNA that are missing or present more than once. These are called copy number variants. If the genome is a book, a microarray checks whether any chapters have been torn out or bound in twice.

It has been a standard first-tier test for years, it is widely available, and for many families it is the test insurance authorizes first. What it cannot do is read the sentences. A single changed letter inside a gene is invisible to it. So a microarray that finds nothing narrows the possibilities without ruling out a genetic explanation.

Fragile X testing

Fragile X testing looks for one specific kind of change: a repeat expansion in the FMR1 gene, where a short sequence of DNA letters is copied over and over far more times than usual. It needs its own test, because standard sequencing does not reliably count those repeats. It is the easiest thing on this list to fall through the gaps, because sequencing feels comprehensive and on this one point is not. Ask directly: has fragile X been ordered separately?

Exome sequencing

Whole exome sequencing reads the protein-coding part of all roughly 20,000 human genes — about 1 to 2% of the genome, but the part where most currently interpretable disease-causing changes sit. It reads the letters themselves, which is why it finds the single-letter changes a microarray cannot. It is not a replacement for a microarray: in the one study here where the same children had both, the two tests mostly found different things — only 2 of the 15 children with a diagnosis got one from both tests (Tammimies 2015).

Genome sequencing

Genome sequencing reads nearly all of the DNA, including the long stretches between genes. It catches some variant types exome sequencing misses, and it is increasingly offered where it is available. The 2021 ACMG guideline treats exome and genome sequencing together, recommending either as a first- or second-tier test for congenital anomalies, developmental delay or intellectual disability (Manickam 2021).

Gene panels

A panel sequences a pre-selected list of genes tied to a particular clinical picture — an epilepsy panel, an intellectual disability panel. Panels are quicker to interpret and often cheaper. Their limit is structural: a panel cannot find anything outside its own list. In the pooled meta-analysis, exome sequencing found a cause in 27.2% of cases against 22.6% for panel sequencing, a difference that did not reach statistical significance (Stefanski 2021).

Why do yield figures differ so much between studies?

Mainly because of who was tested, not because of the technology. You will see very different figures for what sounds like the same test.

The clearest single comparison comes from a study of 258 children with autism recruited consecutively from a developmental pediatric clinic — a realistic mix rather than a hand-picked one. Every child had a microarray; 95 also had exome sequencing as a trio with both parents. Microarray found a molecular diagnosis in 24 children (9.3%). Exome found one in 8 of the 95 (8.4%). Among the 95 children who had both tests, 15.8% had an identifiable genetic cause. The combined yield was significantly higher in the group with the most complex physical features — scored on major congenital anomalies and minor physical anomalies — than in the group with the fewest (Tammimies 2015).

Set that beside the exome figures in the guidelines section above, and beside the pooled autism figure, which the authors of that review drew from cohorts they themselves describe as highly selected (Stefanski 2021). Same tests, different populations. The highest of those figures describes children who already had other medical findings and had reached a genetics service; the lowest describes everyone walking through a developmental clinic door. Neither is wrong. If a lab brochure quotes you one number, ask who was in that study, and are they like my child?

One thing to be skeptical about. You may be told sequencing has “five times the yield” of a microarray. That kind of comparison is put together by placing figures from separate studies of different populations side by side, and it circulates mainly in laboratory marketing. In the one head-to-head study on this page, the authors concluded that the yields of the two tests were comparable — 9.3% for microarray across all 258 children, 8.4% for exome in the 95 who had it (Tammimies 2015). The honest case for sequencing is not that it is five times better; it is that it reads a different and larger part of the genome, that guidelines now support it early, and that combining approaches finds more than either alone.

What can a genetic test result say?

A result comes back one of three ways, and it helps to know all three before the phone rings.

A positive result. The lab has found a change it can classify as pathogenic or likely pathogenic, and considers it sufficient to explain part of your child’s picture. You should get a named condition, a written report and — this is the part to insist on — a plan.

A negative result. Nothing reportable was found. This is the most common outcome. It does not mean there is no genetic contribution, only that this test, reading this part of the genome, with today’s knowledge, found nothing it could interpret. Ask whether re-analysis of the stored data is planned, and when. Genes are described every year that were unknown when your child’s sample was run.

An uncertain result. The ACMG and the Association for Molecular Pathology set out a five-tier classification for sequence variants — pathogenic, likely pathogenic, uncertain significance, likely benign, benign — with criteria for placing a variant in each (Richards 2015). A variant of uncertain significance, usually shortened to VUS, sits in the middle. The lab found a change and cannot yet say whether it matters.

Uncertain results are common, and they are the ones families are least prepared for. A VUS is not a diagnosis, not a warning, and not something to act on medically by itself. It is a reason to ask three questions: what would move this variant into a firm category, is anyone looking, and what should we do in the meantime? Usually the answer to the last is: nothing different. There is more on reading a report in what your results mean.

Should we test as a trio?

If it is available and covered, usually yes: a trio tests your child alongside both parents, so the lab can see which changes were inherited and which are new, which resolves many otherwise uncertain results. Testing your child alone is called proband-only. Ask about trio testing before the sample is taken, because adding parents afterwards means starting parts of the process again.

What are secondary findings in genetic testing?

They are findings unrelated to the reason you tested, which sequencing can turn up because it reads thousands of genes at once. The ACMG maintains a list of genes considered actionable enough to report when found this way; the SF v3.3 policy statement, updated in 2025, names 84 (Lee 2025). Most are tied to heart conditions — rhythm disorders, cardiomyopathies, aortic disease and inherited high cholesterol — or to inherited cancer predisposition, places where knowing early genuinely changes what doctors watch for.

Receiving them is a choice, not an automatic extra: labs generally ask before testing begins, so ask what your lab’s process is. There is no correct answer. Some parents want every actionable finding; others want only what explains the reason they came. Make the choice deliberately rather than by ticking whatever is already ticked, and if your child is old enough to have a view, ask them.

How much does autism genetic testing cost, and who pays?

The range is enormous and the sticker price is rarely what you pay.

MedlinePlus, the National Library of Medicine’s consumer genetics resource, puts it plainly: the cost of genetic testing “can range from under $100 to more than $2,000, depending on the nature and complexity of the test.” A single targeted test sits at the bottom of that range and sequencing at the top, and testing more than one family member — a trio, for instance — raises the total.

That is list price. What an insured family actually pays depends on the plan, on whether prior authorization was obtained, and on whether the lab has a patient-assistance program. It is common for a bill that looks alarming on paper to settle at a fraction of it. It is also possible for a test run without authorization to land in full on a family that assumed it was covered, which is the outcome to protect yourself against.

Three things make coverage more likely. First, a letter of medical necessity from the ordering clinician, setting out the clinical reason for the specific test. Second, prior authorization obtained in writing before the sample goes to the lab. Third, matching the request to the wording insurers recognize — sequencing is generally easier to get approved where there is developmental delay or intellectual disability, which is exactly the population the 2021 ACMG guideline addresses (Manickam 2021).

If your child has Medicaid, check your own state’s policy rather than a national summary: Medicaid genetic-testing coverage is set state by state and varies considerably. Our fuller walkthrough of billing, denials and appeals is on what genetic testing costs and how insurance handles it.

Is it legitimate to decide not to test my child?

Yes. Some families read everything here and decide not to test. That is a legitimate decision, and it is not a failure of diligence.

The reasons are usually good ones. Most results find nothing, so the most likely outcome is an appointment, a needle and a wait for no new information. Uncertain results can create worry that outlasts their usefulness. Some parents do not want a genetic file attached to their child’s name. Some autistic adults are wary of the whole field, for reasons rooted in how genetic knowledge about autism has been used, and a parent who shares that wariness is not being irrational.

Autistic people have the right to decide about their own genetic information. For a young child that decision is held by parents, but it is being held in trust, not owned — and it should get lighter to hold every year. A teenager who does not want to be tested has said something that matters. A teenager who wants to be tested when you would rather not has also said something that matters.

None of this is permanent. Testing that is declined now can be done later; the biology does not expire. If you want a middle path, ask genetics to see you for the conversation without committing to the test — the 2013 ACMG guideline explicitly expects testing options, diagnostic yields and family investment to be discussed before anyone proceeds (Schaefer 2013). Having the conversation and then saying no is a complete and reasonable outcome.

How do I get my child referred for genetic testing?

Ask your pediatrician for a genetics referral. You do not need technical language, and you do not need to justify the request.

Who can order it. A clinical geneticist or a genetic counselor, a child neurologist, or a developmental pediatrician. A general pediatrician can often order a microarray or fragile X test directly and can always write the referral to genetics. If your child has already seen a neurologist for seizures, that clinic is frequently the fastest route.

What to say. Something like this is enough:

“My child has an autism diagnosis. I would like a referral to genetics to discuss testing. I understand that professional guidelines support exome or genome sequencing early where there is developmental delay, and I would like to talk through what would be appropriate for us — including whether fragile X needs its own test.”

If you would rather not say it out loud, put it in the patient portal in writing. A written request also gives you a dated record if the referral goes missing.

What to bring. The diagnostic report, any previous genetic test results — including ones you think were negative, since re-running a test is a waste of everyone’s time — a list of medications, and a short family history: developmental conditions, intellectual disability, epilepsy, miscarriages, early deaths, or relatives who were “always a bit different”. Bring names and rough ages. Also bring your questions, on paper, because appointments move fast.

Saliva or blood. Both are used. Blood usually yields more DNA, and some labs require it for sequencing; saliva or a cheek swab avoids a needle entirely and can sometimes be collected at home. If a needle would make the appointment impossible, say so before it is booked and ask whether a saliva kit is acceptable for the specific test being ordered — for many, it is. If blood is genuinely required, the preparation list further down this page is the one to use. There is more on what is and is not drawn from a sample in blood tests and autism.

Turnaround. MedlinePlus says “it may take a few days to weeks to receive the test results” from the date a sample is taken. At the appointment, ask what turnaround the lab quotes and who will call you. A result sitting unexplained in a patient portal on a Friday night is avoidable, and asking for it to come by phone is a reasonable request.

Direct-to-consumer kits are not this. The ancestry and wellness kits sold online are not clinical genetic testing. They read a limited, pre-chosen set of positions in the genome, they are not designed or validated to diagnose conditions, and their results are not a substitute for a clinical report — a raw data file from one of them cannot answer any of the questions on this page. If you have already bought one, nothing is lost; just do not let it stand in for the real test.

The form at the foot of this page registers your interest with a genetics or testing partner — not with us — if you would like help finding a route to testing rather than doing all the chasing yourself. It is not a referral, no specific lab is chosen for you, and nothing on this page depends on it.

Questions to ask genetics

  1. What exactly are you ordering, and what does that test read?
  2. How often do you find something in a child like mine — and which study is that number from?
  3. Has fragile X been ordered separately?
  4. Is trio testing available, and is it covered?
  5. What would change in my child’s care in the next year if this comes back positive?
  6. How do you handle secondary findings, and when do we make that choice?
  7. If the result is uncertain, who explains it to us, and is re-analysis planned later?
  8. What will this cost us, and has prior authorization been obtained in writing?

Write the answers down. Future clinicians will ask you the same things, and you will not remember which appointment they came from.

Preparing for the blood or saliva draw

  • Ask for the first or the last appointment of the day, when waiting rooms are quietest.
  • Ask whether saliva is acceptable for this specific test before assuming a needle is required.
  • Request numbing cream and ask how long before the appointment it needs to go on.
  • Pack headphones, a preferred video and a snack for afterwards.
  • Tell the staff in advance how your child communicates, and what a distressed moment looks like for them.
  • Ask for the draw to be done by the most experienced person available, and ask them to explain each step before doing it.
  • Plan nothing else for that day. One appointment is enough.

Our fuller accommodation list for clinical appointments is on medical appointments.

Questions parents ask after reading this

  1. Given who my child actually is — other medical features or none — which yield figure on this page describes us, and does that change whether we test?
  2. If the result came back uncertain, what would we do differently the next morning? If the answer is nothing, are we ready for that outcome?
  3. Who in this family gets to decide, and how does that shift as our child gets older?
  4. Are we testing to change medical care, to answer a question we have, or to get something at school — and is testing the right tool for the one we picked?

If you only do three things

  1. Ask your pediatrician, in writing, whether a genetics evaluation has been offered — and ask specifically whether fragile X has been ordered separately.
  2. Before consenting, ask what would change in your child’s care in the next year if the result were positive, and write the answer down.
  3. Decide in advance, with your co-parent and with your child if they are old enough, what you want to do about secondary findings — so you are not deciding it at a desk with a pen in your hand.

Whole exome sequencing · Chromosomal microarray · Fragile X · What testing costs · Understanding your results · Autism testing, explained · Are online autism tests accurate? · Getting assessed · Why autism happens

Questions parents ask

It depends on what you want from it. Most children tested get no explanation back: pooled across the autism cohorts in a systematic review of clinical sequencing studies, the yield was 17.1% (Stefanski 2021). Testing is most worth it when a named condition would change medical care — a heart or kidney scan, a seizure plan, a specialist referral — or when you want the answer for its own sake. It is least worth it if you are hoping the result will explain your child to a school.

Genetics contributes a great deal, but not through a single gene. The June 2026 joint statement from the National Society of Genetic Counselors, the American Society of Human Genetics and the American College of Medical Genetics and Genomics says that "hundreds of genes and chromosomal variations are known to increase the likelihood of autism." Some findings are inherited from a parent, some are new in the child, and many autistic children have no identified genetic finding at all. A genetic counselor can tell you what a specific result means for your family.

MedlinePlus, the National Library of Medicine's consumer genetics resource, says the cost of genetic testing "can range from under $100 to more than $2,000, depending on the nature and complexity of the test." That is the list price, not what an insured family usually pays. Ask the ordering clinic for the lab's patient-responsibility estimate in writing before the sample is taken.

Often, and it depends on the wording of the request. Coverage is generally easier to obtain where there is developmental delay or intellectual disability, which is the population the ACMG's 2021 evidence-based guideline covers when it recommends exome or genome sequencing as a first- or second-tier test (Manickam 2021). Ask your clinician for a letter of medical necessity, ask whether prior authorization is needed, and check your state Medicaid policy separately — it is not the same as your commercial plan.

There is no single fixed list. The 2025 American Academy of Pediatrics clinical report on genetic evaluation says testing should be selected by phenotype where the clinical picture points to a specific condition, and that where it does not, an agnostic — hypothesis-free — approach is used, chosen on diagnostic yield and practical considerations (Rodan 2025). In practice that usually means exome or genome sequencing, or a chromosomal microarray, with fragile X testing ordered separately because sequencing does not reliably detect it.

No. There is no genetic test that detects autism, before diagnosis or at any other point, because autism is diagnosed clinically — from developmental history and observation against the diagnostic criteria the American Academy of Pediatrics expects primary care clinicians to know (Hyman 2020). We do not support or promote prenatal or embryo screening for autism. Prenatal testing exists for specific named genetic conditions, which is a different question, and one for a genetic counselor rather than a website.

MedlinePlus says that from the date a sample is taken, "it may take a few days to weeks to receive the test results," and that the doctor or genetic counselor who orders the test can give you the time frame for that specific test. Ask the ordering clinic for the lab's stated turnaround and for who will call you with the result, so you are not left refreshing a patient portal.

Usually a clinical geneticist, a genetic counselor, a child neurologist or a developmental pediatrician. A general pediatrician can often order a microarray or fragile X test directly, and can always write the referral. If nobody has raised it, asking your pediatrician for a genetics referral is a normal and reasonable request.

No. A result that finds nothing means this test did not find anything it can currently interpret, in the part of the genome it reads. Most autistic children tested get exactly that result, and it does not rule out a genetic contribution. Ask whether re-analysis of the same data is planned later, because interpretation improves as more genes are described.

It is the middle category in the five-tier scheme the ACMG and the Association for Molecular Pathology set out for classifying sequence variants: pathogenic, likely pathogenic, uncertain significance, likely benign, benign (Richards 2015). An uncertain variant is a change the lab found but cannot yet call harmful or harmless. It is not a diagnosis, it is not a warning, and it should not change your child's care on its own.

Written by · Reviewed by the ActNowASD editorial team · · How we check numbers →

Where this comes from

This is health information, not medical advice. It cannot replace a conversation with your child's doctor.